Crizotinib functions by inhibiting specific genetic mutations and rearrangements found in certain cancers. The inhibition of ALK and ROS1 kinases leads to the suppression of downstream signaling pathways, which are critical for tumor growth and survival. This targeted approach allows crizotinib to reduce tumor size and slow disease progression with relatively fewer side effects compared to traditional chemotherapy.
